Primaquine
Administration
- Type: Antimalarial, anti-PCP
- Dosage Forms:
- Routes of Administration: oral
- Common Trade Names:
Adult Dosing
Indications by Disease
| Disease | Dose | Context |
|---|---|---|
| Pneumocystis jirovecii pneumonia | 30mg PO q24hrs | Mild disease with Clindamycin |
| Pneumocystis jirovecii pneumonia | 30mg PO once daily | Severe disease with Clindamycin |
Pediatric Dosing
Indications by Disease
Special Populations
- Pregnancy Rating: D
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing:
- Hepatic dosing:
Contraindications
- Allergy to class/drug
- Concomitant use with other potentially hemolytic or myeloid suppressing drugs
- Acutely ill patients with diseases prone to granulocytopenia (e.g. SLE or rheumatoid arthritis)
Adverse Reactions
Serious
- Hemolytic anemia, leukopenia
- Methemoglobinemia
Common
- Nausea, abdominal pain
Pharmacology
- Half-life: 4-7 hours
- Metabolism:
- Excretion:
Mechanism of Action
- Eliminates tissue infection, thus preventing erythrocytic forms of parasite